Skip to main content
Explore URMC

menu

Kidney Cancer: A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Research Question:
What are the good or bad effects of atezolizumab versus placebo on you and your Renal Cell Carcinoma (RCC)?

Basic Study Information

Purpose:
You will be randomly assigned to one of the following treatment groups: atezolizumab or placebo. Neither you nor your study doctor may choose the group you will be in. You will have a 50/50 chance of being placed in either group.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03024996?term=wo39210&rank=1
Study Reference #: IGUK17001

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Guancial

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351
Email: Ayesha_Khan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Renal Cell

More information about Kidney Cancer

Return to Search